News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advaxis, Inc. Lead Drug ADXS11-001 Well-Tolerated in 72 Patients, to Date



4/19/2011 11:25:58 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Dr. John Rothman, EVP of Science and Operations at Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, gave the lead presentation entitled, “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar held April 16, 2011 entitled “Immunotherapy: a promising way for cancer treatment.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES